ArticleBMC psychiatry2025
Longitudinal effects of atypical antipsychotic drugs on body composition in first-episode and chronic schizophrenia patients.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Visceral Adiposity Is Associated with Elevated Interleukin-1 Receptor Antagonist Levels and Anxiety Symptoms in Schizophrenia.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to investigate the effects of atypical antipsychotic drugs (AAPDs) on changes in body composition and fat distribution characteristics in patients with first-episode schizophrenia (FSCZ) and chronic schizophrenia (CSCZ), as well as to predict their temporal trends.
methodsA total of 70 inpatients (51 FSCZ, 19 CSCZ) admitted to Tianjin Anding Hospital from January 2023 to June 2024 were enrolled. Body composition indicators, including weight (W), Body Mass Index (BMI), waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), abdominal skinfold thickness (ASF), body fat (BF), body fat percentage (BFP), and visceral fat area (VFA) were measured at baseline and every 4 weeks over a 12-week period. A linear mixed-effects model (LMM) was used to analyze dynamic changes, and independent t-tests were used to compare baseline differences.
resultsIn FSCZ patients, W, BMI, WC, ASF, BF, and BFP increased significantly over time (P < 0.05). The olanzapine group (Group A) showed the steepest slopes for W (1.85 kg/4 weeks), BMI (0.70 kg/m²/4 weeks), and WC (3.07 cm/4 weeks) (P < 0.01), indicating central obesity. In CSCZ patients, no significant changes in body composition were observed (P ≥ 0.08), but baseline values of W, BMI, and WC were higher than those of FSCZ patients (P < 0.05). A LMM predicted that FSCZ patients would reach CSCZ levels in W, BMI, and WC in approximately 64, 42, and 28 weeks, respectively, with other indices reaching similar levels within 22.2-67.7 weeks.
conclusionIn this preliminary longitudinal study, AAPDs - particularly olanzapine - were associated with rapid and significant increases in central obesity among FSCZ patients. whereas CSCZ patients exhibited metabolic stability over the short observation period. These findings suggest that both disease stage and treatment phase play critical roles in shaping body fat distribution trajectories. The early phase of antipsychotic treatment may represent a vulnerable period for targeted metabolic monitoring and timely intervention to prevent long-term cardiometabolic risks. While these results provide preliminary evidence for stage-specific metabolic patterns, confirmation in larger, randomized, and longer-term studies is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.